Validating the Predictive Value (of Response to Rituximab Induction and Maintenance) of the FCGR3A 158V/F Polymorphism Using Complimentary Genotyping Methods
- Genotype the full cohort of samples available from the RESORT clinical trial
(ECOG-E4402) for FCGR3A 158V/F in parallel to independently verify results.
- Correlate the FCGR3A 158V/F polymorphisms to response, response duration, and time to
- Quantify copy number variation in FCGR3A in this cohort.
OUTLINE: Archived DNA samples isolate from peripheral blood mononuclear cells and from
formalin-fixed paraffin-embedded tissue samples are analyzed for FCGR3A 158V/F polymorphisms
using different complementary genotyping methods. Assay results are reviewed and compared
with patients' outcome data.
Correlation of FCGR3A 158V/F polymorphisms with response, duration of response, and time to rituximab resistance
Brad S. Kahl, MD
University of Wisconsin, Madison